Literature DB >> 8797807

The significance of Ser1029 of the heat-stable enterotoxin receptor (STaR): relation of STa-mediated guanylyl cyclase activation and signaling by phorbol myristate acetate.

A Wada1, M Hasegawa, K Matsumoto, T Niidome, Y Kawano, Y Hidaka, P I Padilla, H Kurazono, Y Shimonishi, T Hirayama.   

Abstract

To characterize Ser1029 in STaR at a consensus sequence of phosphorylation site by PKC, two mutants of mS1029A with replacement of Ser1029 to Ala1029 and C delta 1029 lacking 22 amino acids including Ser1029 were prepared. Preincubation of the wild type-STaR (wt-STaR) transfectant with 1 microM PMA caused additional STa-mediated guanylyl cyclase (GC) activation compared to control, whereas the mS1029A- and C delta 1029-transfected cells did not show a similar enhanced GC activation by PMA. After metabolic labeling with [32P]phosphate, transfected cells with wt-STaR and mutants were incubated with 1 microM PMA. Subsequent 32P-radiolabeled proteins were immunoprecipitated using anti-STaR antibody, and analyzed by autoradiography after separation on SDS-PAGE. The immunoprecipitated wt-STaR but not mS1029A and C delta 1029 had a significant radioactivity. These results suggest that the effect of PMA on wt-STaR transfectants may be caused by phosphorylation of Ser1029. The C delta 1012 mutant, with further truncation (Gln1012-Phe1050) of the carboxy terminus, did not show STa-mediated GC activation. Based on these data, these 17 amino acids (Gln1012-Ala1028), essential for signaling of GC activation by STa, have an abundance of basic amino acids which might be functionally influenced by phosphorylation of Ser1029.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797807     DOI: 10.1016/0014-5793(96)00284-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Photoreceptor guanylate cyclase variants: cGMP production under control.

Authors:  Izabela Sokal; Andrei Alekseev; Krzysztof Palczewski
Journal:  Acta Biochim Pol       Date:  2003       Impact factor: 2.149

Review 2.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

Review 3.  Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C.

Authors:  Arie B Vaandrager
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

4.  Receptor guanylyl cyclase C (GC-C): regulation and signal transduction.

Authors:  Nirmalya Basu; Najla Arshad; Sandhya S Visweswariah
Journal:  Mol Cell Biochem       Date:  2009-12-04       Impact factor: 3.396

5.  Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis.

Authors:  Nirmalya Basu; Rashna Bhandari; Vivek T Natarajan; Sandhya S Visweswariah
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

Review 6.  Pendrin, a novel transcriptional target of the uroguanylin system.

Authors:  Julia Rozenfeld; Osnat Tal; Orly Kladnitsky; Lior Adler; Edna Efrati; Stephen L Carrithers; Seth L Alper; Israel Zelikovic
Journal:  Cell Physiol Biochem       Date:  2013-12-18

7.  Mutual enhancement of virulence by enterotoxigenic and enteropathogenic Escherichia coli.

Authors:  John K Crane; Shilpa S Choudhari; Tonniele M Naeher; Michael E Duffey
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

8.  Glycosylation of the receptor guanylate cyclase C: role in ligand binding and catalytic activity.

Authors:  Yashoda Ghanekar; Akhila Chandrashaker; Utpal Tatu; Sandhya S Visweswariah
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

9.  Low salt intake down-regulates the guanylin signaling pathway in rat distal colon.

Authors:  Z Li; J W Knowles; D Goyeau; S Prabhakar; D B Short; A G Perkins; M F Goy
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

10.  Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.

Authors:  John C Flickinger; Jeffrey A Rappaport; Joshua R Barton; Trevor R Baybutt; Amanda M Pattison; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-01-20       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.